For many years HMG-CoA reductase inhibitors (commonly referred to as “statins”) have been the mainstay of pharmacological lipid lowering therapy across many patient groups. Hypercholesterolemia is an important and modifiable risk factor for cardiovascular disease, and as such elevated cholesterol that have not responded to lifestyle modifications alone should be addressed with lipid lowering medications. Statins are generally well tolerated with predictable efficacy and side effects. However, limited data exists regarding when and if it is appropriate to cease treatment with statin drugs.
Download the complete bulletin:
A joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041.